FLNA:BMV
Filana Therapeutics Inc
15,92Â MXN
0,00%
(0,00) 1d
5 d’oct., 12:05:31 GMT-6 · MXN
search
Tots els sÃmbols
| SÃmbol | Preu | Canvi | Percentatge de canvi |
|---|
insights_autoS'estan generant les estadÃstiques principals per a FLNA...
Capitalització borsà ria
39,63Â M
Volum mitjÃ
0,00
Volum
1,00
Alt 52 setmanes
56,00Â MXN
Baix 52 setmanes
15,92Â MXN
Nombre d'empleats
19
Capitalització borsà ria
39,63Â M
Volum mitjÃ
0,00
Volum
1,00
Alt 52 setmanes
56,00Â MXN
Baix 52 setmanes
15,92Â MXN
Nombre d'empleats
19
NotÃcies
De fonts web i partners de notÃcies
https://www.dars.gov.et/
·
fa 1 setmana
Filana Therapeutics (FLNA) Eases to $0.92 as Shares Sit Between Firm Support and Overhead Resistance - Low Risk Entry Stocks
Perfil
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. Currently led by President and CEO Richard Barry, Filana is working on developing simufilam to treat tuberous sclerosis complex–related epilepsy. The company previously was developing simufilam as an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice charged an advisor to Cassava Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. Wikipedia
Sobre Filana Therapeutics Inc
Conseller delegat-
Empleats19
Fundació1998
Seu principalAustin, Texas, Estats Units d'Amèrica
Sector-
Lloc webpaintrials.com